According to the latest data from the Hong Kong Stock Exchange, on March 24, a shareholder of KINTOR PHARMA-B (09939) deposited shares with Huatai HK, with a deposited market value of HK$83.8406 million, accounting for 6.11% of the holdings. KINTOR PHARMA-B announced that its self-developed, potentially first-in-class KX-826 Tincture 1.0% for the treatment of hair loss has achieved top-line data in the pivotal Phase III clinical trial. The data shows that the Phase III trial met its primary endpoints, with results demonstrating statistical significance and clinical relevance, as well as excellent efficacy and safety profiles.